New drug YL201 takes on tough esophageal cancer
Disease control
Not yet recruiting
This large Phase 3 trial tests a new drug called YL201 against standard chemotherapy in 440 people with advanced esophageal cancer that has worsened after initial treatment. YL201 is a targeted therapy designed to deliver chemo directly to cancer cells. The study aims to see if i…
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC